A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Study Number: SCRI MS914001_0002
Study Summary:
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Status: Open
Available at Peoria, Galesburg, Ottawa, Washington, Pekin, and Bloomington ILCC clinics
Study Coordinator(s)
- Carrie, 309-243-3661 cgeoffroy@illinoiscancercare.com
- Jessica, 309-243-3615, jjones@illinoiscancercare.com
- Kimberley, 309-243-3618 ksinanan@illinoiscancercare.com
